BIOGEN IDEC STOCKHOLDERS ELECT COMPANY'S BOARD NOMINEES

BIOGEN IDEC STOCKHOLDERS ELECT COMPANY'S BOARD NOMINEES

Cambridge, MA, June 19, 2008 - Biogen Idec Inc. (NASDAQ: BIIB) today announced that, based on a preliminary count provided by its proxy solicitor, stockholders have elected all four of the Company's nominees - Cecil B. Pickett, Ph.D., Lynn Schenk, J.D., Phillip A. Sharp, Ph.D., and Stelios Papadopoulos, Ph.D. - to the Biogen Idec Board of Directors at today's Annual Meeting of Stockholders. In addition, based on that preliminary count, the proposal to amend the Company's bylaws to set the size of the Board at 12 has been defeated. The preliminary count is subject to the official tabulation of vote results, which will be provided by Biogen Idec's independent inspector of elections, IVS Associates, Inc., in approximately 2-3 weeks.

Bruce R. Ross, Biogen Idec's Chairman, said, "We are gratified that our nominees will serve on the Biogen Idec Board of Directors. Our Board has a track record of delivering stockholder value and is committed to pursuing all avenues to continue to do so in the future. We look forward to turning our undivided attention to delivering strong performance and growing our business for stockholders."

About Biogen Idec
Biogen Idec creates new standards of care in therapeutic areas with high unmet medical needs. Founded in 1978, Biogen Idec is a global leader in the discovery, development, manufacturing and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec's significant products that address diseases such as lymphoma, multiple sclerosis and rheumatoid arthritis. For product labeling, press releases and additional information about the company, please visit www.biogenidec.com.

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.